Anderson N G, Lieberman S
Endocrinology. 1980 Jan;106(1):13-8. doi: 10.1210/endo-106-1-13.
The pathways of biosynthesis of the estrogens from C19 steroids has been examined by in vitro kinetic experiments using human placental microsomes and two precursors, each labeled with a different radioisotope. The results indicate that under the conditions employed, androstenedione is an obligatory intermediate in the conversion of 3 beta-hydroxy-5-androsten-17-one (dehydroisoandrosterone) or its sulfate, dehydroisoandrosterone sulfate, into estrone and estradiol. The same result was obtained when the microsomal fraction was replaced by either a 1000 x g supernatant preparation from human placenta or a homogenate of placental mitochondria. If alternative pathways involving C19-hydroxylated derivatives of dehydroisoandrosterone or its sulfate exist, they appear to be of minor quantitative significance.
利用人胎盘微粒体和两种分别用不同放射性同位素标记的前体,通过体外动力学实验研究了从C19类固醇生物合成雌激素的途径。结果表明,在所采用的条件下,雄烯二酮是3β-羟基-5-雄烯-17-酮(脱氢异雄酮)或其硫酸盐硫酸脱氢异雄酮转化为雌酮和雌二醇过程中的必需中间体。当微粒体部分被人胎盘的1000×g上清液制剂或胎盘线粒体匀浆替代时,也得到了相同的结果。如果存在涉及脱氢异雄酮或其硫酸盐的C19-羟基化衍生物的替代途径,它们在数量上似乎意义不大。